Mst (Morphine Sulfate Ph. Eur.)

Morphine sulfate, the active ingredient in Mst, is an opioid analgesic presented as an oral formulation for oral use. It is indicated for the management of moderate to severe acute pain and chronic cancer‑related pain in adult patients, and is classified as a Schedule II controlled substance in the EU.

GNH USA supplies Mst as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory support for importers, and ensures timely delivery across global markets.

Morphine sulfate is an opioid analgesic used in the management of pain.

Moderate to severe acute pain: provides rapid analgesia for postoperative, trauma‑related, or injury‑induced pain, improving patient comfort. Chronic cancer pain: maintains long‑term pain control in oncology patients, helping to improve quality of life during disease progression. Severe breakthrough pain: offers supplemental opioid relief when baseline analgesic regimens are insufficient, allowing timely pain breakthrough management. Pain associated with myocardial infarction: reduces chest discomfort and anxiety during acute coronary events, facilitating early medical intervention.

Common Side Effects: - Nausea: feeling of sickness that may lead to vomiting. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or fatigue. - Dry mouth: reduced salivation causing oral dryness.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure leading to faintness. - Addiction or dependence: compulsive use despite harmful consequences.

Precautions should be taken when prescribing morphine sulfate to ensure patient safety.

Assess pain severity and opioid tolerance: evaluate before initiating therapy. Avoid use in patients with significant respiratory depression: monitor ventilation closely. Use caution in renal or hepatic impairment: consider dose adjustments as needed. Do not combine with other central nervous system depressants without supervision: risk of additive effects. Educate patients on signs of overdose and safe storage. Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Drug interactions can alter the efficacy or safety of morphine sulfate.

Major Interactions (Avoid): - Concomitant use with other opioids: risk of profound respiratory depression. - Benzodiazepines or barbiturates: additive central nervous system depression. - MAO inhibitors: risk of severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase morphine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic efficacy. - Anticholinergics: may worsen constipation.